MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

NCT01959165 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: MEDI7183 low dose
DRUG: MEDI7183 medium dose
DRUG: MEDI7183 high dose
DRUG: Matching Placebo

Sponsor

AstraZeneca